Therapeutic Targeting of the DNA Damage Response

Please contact for Microsoft Teams link

Dr. Graeme Smith is the Chief Scientific Officer at Artios Pharma with responsibility for the scientific strategy and drug discovery projects in the DNA Damage Response (DDR) area. Prior to Artios, Dr. Graeme Smith held the positions of Senior Project Leader and Executive Director of Bioscience at AstraZeneca within the Oncology therapy area. In these roles Dr. Smith led teams in the discovery and development of novel anti-cancer agents delivering novel therapies into the clinic. Dr. Smith was Research Director at KuDOS Pharmaceuticals where he was a co-inventor of Lynparza™ (olaparib), the first PARP inhibitor to reach the market in 2014.